1. Sanofi, despite the pandemic, sees early gains from CEO Hudson's strategy — Trump administration to require insurers to cover COVID-19 vaccine — Regeneron/Sanofi's Libtayo gets priority review in NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

IC year end haul

Discussion in 'Kowa Pharmaceuticals' started by anonymous, Dec 27, 2018 at 12:06 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    How is everyone lookin' on their 4th quarter? Gonna go over or under the 21K?
     

  2. anonymous

    anonymous Guest

    Under for the first time in my career. Humana Medicare is killing me.
     
  3. anonymous

    anonymous Guest

    I feel you on that. I barely made it but Humana was a thorn in my side all year...